Pfizer CEO Albert Bourla shared insights about his dinner with Robert F. Kennedy Jr., Donald Trump's nominee for health secretary. While discussing their conversations, Bourla highlighted common interests in chronic diseases rather than their differences on vaccines. He expressed cautious optimism about the new administration, emphasizing potential opportunities amidst concerns about radical changes. Bourla believes the administration will be prudent in health management, especially to avoid another crisis, indicating an overall positive outlook for collaboration between Pfizer and the forthcoming government policies.
'And those are things in chronic diseases, in cardiovascular diseases, and more importantly, in cancer, which is something that is very, very high in the mind of the president.'
'I think there are a lot of opportunities that probably outweigh the risks that we have with the radical change that we will see from the Trump administration.'
Collection
[
|
...
]